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Abstract: The diverse abilities of cerium oxide nanoparticles (CONPs) have encouraged researchers to pursue
CONPs as a therapeutic agent to treat a number of diseases, including cancer. In vitro and in vivo studies have
shown CONPs to be toxic to cancer cells, inhibit invasion, and sensitize cancer cells to radiation therapy. However,
CONPs display minimal toxicity to normal tissues and provide protection from various forms of reactive oxygen species (ROS) generation. The antioxidant capabilities of CONPs, which enable radiation protection, have also resulted
in the exploration of these particles as a potential treatment for other disorders characterized by ROS accumulation, such as diabetes and macular degeneration. While critical information regarding the uptake, retention, and
clearance of these particles is incomplete and conflicting reports exist about in vitro toxicity, most research into the
various applications of CONPs has yielded promising data. This review highlights the current research into cerium
oxide nanoparticles as a novel therapeutic for the treatment of cancer and other diseases.
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Introduction
In recent years, nanotechnology has become a
main focus of biomedical research. Nanoparticles applications include drug delivery systems,
luminescent biomarkers, and tissue engineering, among others [1]. In particular, cerium
oxide nanoparticles (CONPs), which consist of a
cerium core surrounded by an oxygen lattice,
have shown promise in a number of applications. Originally of interest for the ability of surface oxygen vacancies to interact with and
modulate free radicals, CONPs have since been
shown to display a number of antioxidant
behaviors, including superoxide dismutase
(SOD) activity [2], catalase mimetic activity [3],
nitric oxide radical scavenging [4], and hydroxyl
radical scavenging [5]. However, tissue or cell
environmental conditions appear to play an
important role in the determination of activity,
as CONPs also possess direct oxidant behavior
[6]. To date, pH is one of the few factors shown
to drive whether CONPs act as oxidants or antioxidants [7, 8].
As cellular levels of reactive oxygen species
(ROS) are tightly controlled in normal, healthy

cells [9], the ability to modulate the redox status of cells has applications in diseases where
ROS levels have become de-regulated or are
altered by treatment. Though more recently
linked to cell proliferation and survival, ROS
accumulation is generally associated with
undesired effects, having been linked to neurodegenerative diseases, diabetes, atherosclerosis, and even aging [9]. In cancer, which causes
over 500,000 deaths per year [10], ROS can
drive both the initial development and progression, as well as down regulate antioxidant
enzymes that normally combat radical production [11]. Studies have shown CONPs to possess innate cytotoxicity to cancer cells, antiinvasive properties, and the ability to sensitize
cancer cells to radiation induced cell death,
while protecting the surrounding normal tissues
(Figure 1). Additionally, CONP treatment has
been shown to prevent macular degeneration
[12] and the formation of neovascular lesions in
the retina [13], as well as decrease hepatic ROS
levels linked to the progression of diabetes
[14]. Thus, CONPs have extensive potential as a
therapeutic agent for the treatment of cancer,
as well as other diseases in which ROS have

Cerium oxide nanoparticles and human diseases

Figure 1. Potential therapeutic applications of CONPs. The various diseases in which CONPs have been tested and
ROS-related therapeutic mechanisms are illustrated.

been implicated. Potential applications of
CONPs are summarized in Figure 1 with brief
description of ROS-dependent mechanisms
that are discussed in further details below.
CONP effect on cancer
Anti-invasive properties
In addition to CONPs’ toxicity to cancer cells in
vitro and in vivo, studies have shown polymercoated CONPs to also manipulate tumor-stromal interactions to the detriment of tumor progression and invasion [15]. Polymer coating of
CONPs increases aqueous solubility [7], yet
does not appear to impact CONP redox activities [6, 15]. Epithelial/stromal signaling is
largely mediated by myofibroblasts, which play
a key role in the expression of extracellular
matrix components, including α-smooth muscle actin and collagen, to facilitate tumor invasion and angiogenesis [16]. With the transition
from fibroblast to myofirbroblast driven by
transforming growth factor beta 1 (TGFβ1)
-induced ROS-dependent expression of
α-smooth muscle actin, data shows CONPs
possess the ability to modulate myofibroblast
formation [15]. Pre-treatment with CONPs mitigated both TGFβ1-induced α-smooth muscle
actin expression in fibroblasts and the corre-
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sponding myofibroblast transition [15]. As some
myofibroblasts localize to the invasion front of
tumors, CONP treatment diminished the ability
of myofibroblasts to induce invasion by squamous tumor cells in vitro [15]. Interestingly,
CONPs were also able to decrease the intrinsic
ability of cultured squamous tumor cells to
invade, even in the absence of any myofibroblast stimulation [15]. Taken together, these
data demonstrate the direct negative effects of
CONPs on cancer cells, as well as their ability to
modulate the tumor environment and indirectly
inhibit tumor cell invasion.
Radio-protection and radio-sensitization
The ability of CONPs to modulate ROS has led
to their exploration for the improvement of a
current cancer treatment: radiation therapy
(RT). In addition to surgery and chemotherapy,
RT remains a mainstay in the treatment of cancer, with nearly half of all cancer patients
receiving RT at some point during treatment
[17]. Many harmful side effects are associated
with the RT, including fatigue, nausea, and dermatitis, yet few radiation adjuvants are available to mitigate these painful outcomes. For
example, Amifostine, which remains the only
clinically available radio-protectant [17], is itself
associated with nausea and hypotension [18].
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The dual capabilities of CONPs to act as an
antioxidant in normal cells, yet oxidant in cancer cells, supports the role of CONPs as an
adjuvant for RT that could significantly impact
patient quality of life.
In line with the protection from other methods
of inducing oxidative stress, several publications have shown that treatment with CONPs
prior to RT exposure decreases the RT-induced
cell damage and death in normal tissues of the
gastrointestinal tract [19], lung [20], breast
[21], and head and neck [22]. Mechanistically,
CONP radical scavenging inhibited the resulting
caspase 3 activation in irradiated colonic crypt
tissue [19], as well as capsase 3 and 7 activation in irradiated lung fibroblasts in culture [20].
CONPs also increased super oxide dismutase 2
(SOD2) expression up to two-fold in a dose
dependent manner in normal human colon
cells in vitro, while increasing SOD2 expression
by 40% in colonic crypt cells from mice treated
with CONPs [19]. Together, these data indicate
that CONPs protect normal cells both directly,
by scavenging cellular ROS, and indirectly, by
priming cells to respond to ROS insult.
Conversely, in cancer cells with acidic pH, pretreatment with CONPs has been shown to
enhance the ability of RT to induce cell death.
As predicted [7], a most recent publication
demonstrated the ability of CONPs to drive
RT-induced ROS levels in pancreatic cancer
cells [8]. As acidic pH has been shown to inhibit
the catalase activity of CONPs [15], it is suggested that CONPs in cancer cells are only
capable of catalyzing the conversion of highly
unstable superoxide to far more stable H2O2.
Without the ability to act as a catalase mimetic
and remove H2O2, CONPs actually enhance the
toxicity of RT in cancer cells by encouraging the
accumulation and stability of ROS in the cell
[8]. These effects resulted in the radio-sensitization of pancreatic cancer, significantly
decreasing cell viability in vitro [8]. In a pancreatic tumor bearing mouse model that received
the combination therapy of CONPs prior to RT,
significant decreases in tumor weight and volume correlated with an increase in the number
of apoptotic cells in the tumors [8]. Overall,
these data demonstrate that CONPs modulate
ROS in cancer cells such that, not only are there
direct toxic effects, but the therapeutic properties of CONPs extend to radio-sensitization of
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cancer cells and potentially sensitization to
other ROS-inducing therapies.
CONP effect on other diseases
Beyond cancer, several other diseases are
characterized by ROS accumulation. The incidence and progression of neurodegenerative
diseases is often linked with the buildup of
ROS, which becomes detrimental as it overwhelms cellular mechanisms to combat oxidative stress [13]. Increased ROS provides the
primary link between the cause of the disease
and the associated neurodegeneration in
Huntington Disease, Parkinson Disease,
Alzheimer Disease, and age related macular
degeneration (AMD) [13]. While researchers
have yet to truly explore the potential therapeutic benefits of CONPs in many of these diseases, CONPs have been shown to scavenge ROS
in mouse models of hereditary retinal degeneration, preventing deterioration of retinal function, as well as apoptosis in photoreceptor cells
[12]. In a specific AMD model, CONPs scavenged ROS to prevent the associated increase
in vascular endothelial growth factor (VEGF)
expression in photoreceptor cells, thereby preventing intra-retinal and sub-retinal neovascular lesions which lead to blindness [13].
Excitingly, CONP treatment was also able to
induce the regression of pre-existing pathologic
retinal neovasculature suggesting the antiangiogenic function of CONPs [13], and has
been suggested to be applicable for the treatment of other ocular disorders, such as diabetic retinopathy [12, 13].
In the context of diabetes, increased ROS,
especially in the liver which is responsible for
removing free radicals, is established to be an
important factor in the development and progression of the disease [14]. CONP treatment
of diabetic rats was able to return hepatic ROS
levels to levels comparable to those in non-diabetic rats, as well as decrease plasma triglycerides and increase plasma HDL [14]. As many
patients with insulin dependent diabetes
require pancreatic islet transplantation, CONPs
have also been tested for their ability to improve
pancreatic islet function during isolation and
transplantation procedures, during which oxidative stress is an issue [23]. Pre-treatment
with CONPs was shown to significantly increase
viability and insulin secretion, while decreasing
ROS levels in isolated, cultured pancreatic islet
Am J Transl Res 2013;5(2):126-131
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Figure 2. pH-dependent activity of CONPs as pro- or anti-oxidants. In a neutral pH environment, CONPs act as antioxidants that are cytoprotective. On the contrary, in an acidic pH environment, for example in cancer cells, CONPs
function as pro-oxidants that are cytotoxic. Yet other factors likely exist that contribute to the switch between the
pro-and anti-oxidant functions of CONPs.

cells [23]. Overall, CONPs show promise for
addressing the various radical associated problems driving and resulting from diabetes.
Cellular uptake and localization of CONPs
CONPs have been shown to enter mammalian
cells in both normal and diseased states [15,
24, 25], with significant uptake occurring within
3 hours of exposure in culture [26]. CONPs
appear to take multiple routes into cells, as
uptake has been suggested to occur via receptor-mediated endocytosis in both lung cancer
and normal lung cell lines [27], while other
studies have shown CONP uptake via clathrinmediated and calveolae-mediated endocytitic
pathways [26]. There is some debate about the
fate of CONPs once inside the cell. Some studies show that CONPs accumulate in the cytoplasm without translocation to the nucleus [15,
24]. Other studies have demonstrated that
CONPs accumulate primarily in the peri-nuclear
space [28], while still others detected CONPs
co-localized with the mitochondria, endoplasmic reticulum, lysosomes, as well as diffused
throughout the cytoplasm and nucleus [26].
Particle size and surface charge appear to be
determinants of CONP uptake and cellular
localization [7]. As the differential pH of various
sub-cellular localizations has been shown to be
a determinant of CONPs’ anti- or pro-oxidant
activity [7], manipulation of CONPs to target
specific cells or sub-cellular locations is a path
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that has yet to be fully elucidated and exploited
(Figure 2).
Biodistribution and biopersistence of CONPs
Several reports have shown CONPs (<10 nm) to
be well tolerated by animals without inducting
overt toxicity or an immune response across a
range of doses [19, 20, 29]. When administered intravenously (i.v.) or intraperitoneally
(i.p.), studies show that CONPs accumulate primarily in the spleen and liver, to a lesser extent
in the lungs and kidneys, but not in the heart or
brain [29, 30]. Tissues such as the breasts and
pancreas have not been analyzed for retention,
yet nearly half of the injected CONPs remained
in undetermined locations within the body [30].
Further, CONPs were not readily cleared, persisting in the animals for at least 30 days without any appreciable CONP concentration in the
urine or feces [29, 30], suggesting that other
CONP destinations within the body have yet to
be identified.
CONP toxicity
Despite the apparent lack of toxicity in animal
models, reports provide conflicting data about
the toxicity of CONPs in vitro, likely attributable
to the impact of undetermined cellular and
environmental factors on the manifestation of
anti- or pro- oxidant behavior. CONPs are toxic
to bronchial epithelial lung fibroblasts in culture
[28], but non-toxic to mammary epithelial cells
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[21], macrophages [31], immortalized keratinocytes [26], or immortalized pancreatic epithelial cells [8]. In normal cells to which they are not
toxic, the physiological pH is an environment
which enables canonical radical scavenging by
CONPs. Therefore, CONPs introduced prior to
ROS insult confer protection from the effects of
oxidative stress in vitro and in vivo [13, 32-34].
However, published data indicates that CONPs
are toxic to several types of human cancer cells
in vitro, including squamous cell carcinoma
[15], alveolar epithelial cancer cells [35], and
pancreatic carcinomas [8]. Additionally, CONPs
also display toxicity to pancreatic tumors in
vivo, reducing tumor volume by almost 40% [8].
Cellular toxicity is attributed to the generation
of ROS [8, 15] and the induction of oxidative
stress [35], at least in part by the inherent oxidase activity of the nanoparticle core at acidic
pH similar to that of cancer cells [6]. In particular, CONP treatment has been shown to induce
glutathione oxidation, lipid peroxidation, and
membrane damage in lung cancer cells [35].
Further experiments have demonstrated that
generation of CONPs with a negative surface
charge can induce preferential accumulation in
acidic lysosomes within the cell, resulting in
increased toxicity selectively in cancer cells [7].
Conclusions
Despite conflicting in vitro data regarding toxicity, in vivo data about the toxicity and application of CONPs for the treatment of numerous
diseases remains overwhelmingly positive thus
far. In contrast with currently available ROS
modulators, which are characterized by a short
half-life and usually require the introduction of
one antioxidant molecule for each radical to be
scavenged, CONPs persist in the body with a
single particle scavenging many free radicals or
inducing the oxidation of several targets
through its auto-regenerative capacity [12].
With ROS and oxidative stress linked to so
many conditions, the number of potential applications for CONP-based therapies appears
countless. While current research into the therapeutic applications of CONPs leaves some
questions unanswered, it provides a firm basis
and evidence of a bright future for the pharmaceutical application of CONPs in cancer, diabetes, and other ROS-linked disorders that have
yet to be pursued.
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